4-[[4-[[1-(4-chlorophenyl)cyclopropyl]amino]-6-(2,2,2-trifluoroethoxy)-1,3,5-triazin-2-yl]amino]-N-[2-(2,2-dimethylpropylamino)ethylsulfonyl]benzamide | 1360826-46-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 三嗪类
• 英文名称: 4-[[4-[[1-(4-chlorophenyl)cyclopropyl]amino]-6-(2,2,2-trifluoroethoxy)-1,3,5-triazin-2-yl]amino]-N-[2-(2,2-dimethylpropylamino)ethylsulfonyl]benzamide
• CAS: 1360826-46-5
• 化学式: C₂₈H₃₃ClF₃N₇O₄S
• 分子量: 656.129
• InChiKey: WXGOVQCXASWGBF-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  6.2
• 重原子数：
  44
• 可旋转键数：
  14
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.43
• 拓扑面积：
  156
• 氢给体数：
  4
• 氢受体数：
  13

反应信息

• 作为产物：
  描述：

  4-(4-(1-(4-chlorophenyl)cyclopropylamino)-6-(2,2,2-trifluoroethoxy)-1,3,5-triazin-2-ylamino)benzoic acid 在 盐酸 、 benzotriazol-1-yloxyl-tris-(pyrrolidino)-phosphonium hexafluorophosphate 、 三乙酰氧基硼氢化钠 、 溶剂黄146 、 N,N-二异丙基乙胺 作用下， 以 1,4-二氧六环 、 二氯甲烷 为溶剂， 反应 77.0h， 生成 4-[[4-[[1-(4-chlorophenyl)cyclopropyl]amino]-6-(2,2,2-trifluoroethoxy)-1,3,5-triazin-2-yl]amino]-N-[2-(2,2-dimethylpropylamino)ethylsulfonyl]benzamide
  参考文献：
  名称：

  Functionalized triazines as potent HCV entry inhibitors

  摘要：

  A series of potent and novel acylsulfonamide-bearing triazines were synthesized and the structure-activity relationships (SARs) as HCV entry inhibitors were evaluated. This acylsulfonamide series was derived from an early lead, 4-(4-(1-(4-chlorophenyl)cyclopropylamino)-6-(2,2,2-trifluoroethoxy)-1,3,5-triazin-2-ylamino)benzoic acid wherein the carboxylic acid was replaced with an acylsulfonamide moiety. This structural modification provided a class of compounds which projected an additional vector off the terminus of the acylsulfonamide functionality as a means to drive activity. This effort led to the discovery of potent analogues within this series that demonstrated sub-nanomolar EC50 values in the HCV pseudotype particle (HCVpp) assay. (C) 2016 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2016.12.038

文献信息

• US8765944B2
  申请人：——

  公开号：US8765944B2

  公开（公告）日：2014-07-01
• Functionalized triazines as potent HCV entry inhibitors
  作者：Eric S. Mull、Li-Qiang Sun、Qian Zhao、Betsy Eggers、Kevin Pokornowski、Guangzhi Zhai、Ramkumar Rajamani、Susan Jenkins、Melissa Kramer、Ying-Kai Wang、Hua Fang、Daniel Tenney、Carl J. Baldick、Mark I. Cockett、Nicholas A. Meanwell、Paul M. Scola

  DOI：10.1016/j.bmcl.2016.12.038

  日期：2017.2

  A series of potent and novel acylsulfonamide-bearing triazines were synthesized and the structure-activity relationships (SARs) as HCV entry inhibitors were evaluated. This acylsulfonamide series was derived from an early lead, 4-(4-(1-(4-chlorophenyl)cyclopropylamino)-6-(2,2,2-trifluoroethoxy)-1,3,5-triazin-2-ylamino)benzoic acid wherein the carboxylic acid was replaced with an acylsulfonamide moiety. This structural modification provided a class of compounds which projected an additional vector off the terminus of the acylsulfonamide functionality as a means to drive activity. This effort led to the discovery of potent analogues within this series that demonstrated sub-nanomolar EC50 values in the HCV pseudotype particle (HCVpp) assay. (C) 2016 Elsevier Ltd. All rights reserved.